Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT00349830
Status
Recruiting
Apply to this trial

Conditions

  • Carcinomas (Including Squamous Cell and Adenocarcinoma)
  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • blood draw — PROCEDURE

Study Details

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Key Dates

Start date
Jan 31, 2002
Status verified
Feb 2026
Primary completion
Jan 31, 2032
Completion
Jan 31, 2032

Study Design

Enrollment
2,000 participants (estimated)

Primary Outcome Measure

Biomarkers for disease [ Time Frame: Day one ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305
Rene Bonilla
[email protected]
650-498-7703
Maximilian Diehn (PRINCIPAL_INVESTIGATOR)

Find similar trials in Stanford, CA

By research site
Stanford University School of Medicine· Stanford, CA

Related Studies